RLAY News & Events

Reports Q4 revenue $7M, consensus $4.97M. "Our focus on disciplined execution to date has strengthened the foundation of Relay, aligning our organization to support long-term success. In 2026, Relay is entering a pivotal period defined by multiple upcoming clinical milestones across our zovegalisib program, which recently received Breakthrough Therapy designation from the FDA," said Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics. "We anticipate presenting Phase 1/2 breast cancer data at the upcoming ESMO TAT Congress, reporting initial data in PIK3CA-driven vascular anomalies, and providing updates on our breast cancer triplet data and frontline Phase 3 development plans. These milestones position us to deliver meaningful updates in areas with significant unmet need for patients, while continuing to build momentum toward potential commercialization."

Relay Therapeutics announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy designation, BTD, to zovegalisib in combination with fulvestrant for the treatment of adults with PIK3CA mutant, hormone receptor positive, human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer following recurrence or progression on or after treatment with a CDK4/6 inhibitor.